Last updated: September 3, 2026
Epinephrine bitartrate; prilocaine hydrochloride is an established dental local-anesthetic combination, commonly associated with Citanest Forte Dental, a 4% prilocaine hydrochloride injection containing epinephrine at a 1:200,000 concentration. The product is a mature small-molecule injectable with limited product-level financial disclosure, no meaningful biologic or biosimilar risk, and substantial competition from articaine, lidocaine, mepivacaine and other dental anesthetics. Its commercial outlook is stable to declining in developed markets, with revenue dependent on dental-procedure volumes, distributor access, manufacturing reliability and price competition rather than patent exclusivity.
What is epinephrine bitartrate and prilocaine hydrochloride used for?
The combination is used to produce local or regional anesthesia during dental procedures. Prilocaine blocks sodium channels and inhibits nerve conduction. Epinephrine constricts local blood vessels, slowing prilocaine absorption and extending anesthetic duration.
| Attribute |
Product profile |
| Active anesthetic |
Prilocaine hydrochloride |
| Vasoconstrictor |
Epinephrine bitartrate |
| Common concentration |
Prilocaine HCl 4% |
| Common epinephrine concentration |
1:200,000 |
| Primary setting |
Dental offices and oral surgery |
| Dosage form |
Injectable dental cartridge or vial |
| Therapeutic class |
Local anesthetic |
| FDA reference product commonly associated with combination |
Citanest Forte Dental |
| Biologic status |
Small molecule |
| Biosimilar exposure |
None |
The formulation is used when a longer duration of anesthesia or better local retention is desired than may be obtained with plain prilocaine. Its use is constrained by prilocaine-associated methemoglobinemia risk, particularly at high cumulative doses or in susceptible patients.[1]
What is the FDA regulatory status of Citanest Forte Dental?
Citanest Forte Dental is an older FDA-approved dental local anesthetic product associated with NDA 017455. The product’s regulatory history dates to the early period of modern FDA drug approvals, and it does not rely on contemporary regulatory exclusivity to protect its market position.[2]
The public FDA record does not indicate meaningful remaining new-drug exclusivity. The commercial issue is therefore product availability, manufacturing and distribution rather than protection from generic competition.
Does the product have FDA market exclusivity?
No commercially meaningful period of new chemical entity, orphan-drug or pediatric exclusivity remains. Any historical exclusivity associated with the original approval has expired.
The product is a conventional small-molecule injectable. It is not subject to the reference-product exclusivity framework used for biologics, and a biosimilar pathway is not relevant.
Is epinephrine-prilocaine currently marketed in the United States?
Historical FDA labeling confirms the product and formulation. Commercial availability can vary by manufacturer, distributor and presentation. Dental anesthetic products are frequently affected by inventory conditions, cartridge supply, manufacturing changes and wholesaler allocation.
A product can remain FDA-approved while having limited or intermittent commercial distribution. That distinction matters for revenue analysis: regulatory status does not establish current sales volume or active promotional investment.
What patents protect epinephrine bitartrate and prilocaine hydrochloride?
The core active ingredients are old compounds, and composition-of-matter patents for prilocaine and epinephrine do not provide current market exclusivity. The combination is commercially exposed to generic and alternative-product competition.
| Patent category |
Current commercial relevance |
| Prilocaine composition patent |
Expired |
| Epinephrine composition patent |
Expired |
| Fixed-dose combination patent |
No material current exclusivity identified |
| Dental cartridge formulation patent |
Any historical protection is unlikely to block current competition |
| Method-of-use patent |
No meaningful blocking protection identified |
| Manufacturing-process patent |
Could remain confidential, but would not prevent competing products |
| Orange Book patent listing |
No current blocking patent protection is apparent in the public FDA record |
The principal intellectual-property barrier is weak. A manufacturer could still hold know-how involving cartridge filling, sterilization, container closure, stability or supply-chain controls. Those assets may reduce operational competition, but they do not create the same legal protection as an unexpired composition or formulation patent.
What formulations are protected by patents?
The commercially relevant formulation contains prilocaine hydrochloride and epinephrine bitartrate in an injectable dental presentation. Historical formulation and process rights may have covered concentration, pH control, preservative strategy, cartridge materials or manufacturing methods. Those rights are unlikely to provide broad exclusion today.
Dental anesthetic manufacturers can compete through:
- Different anesthetic molecules
- Different vasoconstrictor concentrations
- Plain, non-vasoconstrictor formulations
- Cartridge sizes
- Unit-dose packaging
- Stability and shelf-life performance
- Distribution and private-label agreements
The practical competitive moat is therefore operational rather than patent-based.
When does epinephrine-prilocaine lose exclusivity?
The product lost meaningful exclusivity decades ago. The precise expiration date of every historical patent is less important than the current market structure: the active ingredients are long-established, competing products are available, and no substantial regulatory exclusivity remains.
Are there Paragraph IV challenges?
A Paragraph IV challenge is relevant when an ANDA applicant certifies that a listed patent is invalid, unenforceable or will not be infringed. Because the product has no apparent current blocking Orange Book patent estate, a Paragraph IV event is not the central entry risk.
Generic or follow-on competition can proceed through an ANDA or another FDA pathway without waiting for a modern patent cliff. The market is better characterized as an already genericized market than as a branded product approaching first generic entry.[3]
Which companies are challenging the product?
No major, publicly disclosed Paragraph IV litigation campaign is associated with the epinephrine-prilocaine combination in the available FDA product record. Competition is more likely to arise from established dental-anesthetic manufacturers and private-label suppliers than from a single high-profile patent challenger.
How does epinephrine-prilocaine compare with competing dental anesthetics?
The combination competes primarily on clinical suitability, duration, safety profile, availability and price.
| Product class |
Typical competitive position |
Principal advantage |
Principal limitation |
| Prilocaine HCl with epinephrine |
Mature niche product |
Effective anesthesia with vasoconstrictor support |
Methemoglobinemia risk |
| Articaine HCl with epinephrine |
Strong dental competitor |
High diffusion and broad dental adoption |
Not suitable for every patient or procedure |
| Lidocaine HCl with epinephrine |
Established standard |
Familiarity, broad availability and low cost |
May have shorter or less favorable duration in some procedures |
| Mepivacaine plain |
Alternative when vasoconstrictor is undesirable |
No vasoconstrictor |
Shorter duration and different clinical profile |
| Bupivacaine HCl with epinephrine |
Long-duration option |
Extended postoperative analgesia |
Slower onset and greater toxicity concerns |
| Prilocaine-lidocaine topical systems |
Adjacent products |
Needle-free or topical use |
Different indications and delivery economics |
Articaine with epinephrine is the most important direct commercial comparator in many dental markets. Lidocaine with epinephrine remains a low-cost reference product. The competitive position of prilocaine depends on practitioner preference, patient risk factors and local procurement contracts.
What market dynamics affect epinephrine-prilocaine revenue?
The product operates in a mature, low-growth market. Demand is driven by procedure volumes rather than increased treatment duration or premium pricing.
Dental procedure volume
Higher dental utilization supports local-anesthetic demand. Drivers include dental insurance coverage, disposable income, aging populations, oral-surgery volumes and access to dental care. Economic downturns can delay elective dental treatment and reduce unit demand.
Product substitution
Dentists can switch among multiple anesthetic molecules with limited workflow disruption. This makes demand price-sensitive and weakens brand loyalty. A distributor stockout can shift purchases toward articaine or lidocaine quickly.
Supply-chain exposure
Dental cartridges require specialized filling, sterilization, packaging and quality-control processes. Shortages may arise from:
- Cartridge component constraints
- Sterilization capacity
- Epinephrine stability issues
- Manufacturing deviations
- Raw-material availability
- Wholesaler allocation
- Regulatory remediation
Supply reliability can matter more than patent position. A manufacturer with dependable cartridge production may gain share even without a differentiated formulation.
Safety and labeling
Prilocaine carries a methemoglobinemia warning. This can limit use in patients with congenital or acquired methemoglobinemia, infants, patients receiving oxidizing drugs and other higher-risk groups.[1] Safety considerations support substitution toward lidocaine or other agents when clinicians want to avoid prilocaine-specific risk.
What is the financial trajectory of epinephrine-prilocaine?
Product-level revenue is not publicly reported in major issuer filings. The combination is generally included within broader dental, pharmaceutical or healthcare-consumables categories. An exact revenue series, market share and operating margin cannot be established from public company disclosures.
The financial trajectory can nevertheless be characterized:
| Period |
Financial profile |
| Original launch period |
Protected or branded product economics |
| Genericization period |
Price and share pressure from competing local anesthetics |
| Mature-market period |
Stable procedural demand with limited pricing power |
| Current outlook |
Low-growth or declining unit economics, offset by recurring dental demand |
| Upside case |
Supply disruption at competitors, distributor wins or geographic expansion |
| Downside case |
Price erosion, product discontinuation, safety-driven substitution or manufacturing interruption |
Revenue is likely to be recurring but modest relative to large pharmaceutical products. The product does not have the characteristics of a high-growth specialty medicine: there is no patent-protected premium, no large untreated population created by a new indication and no biologic manufacturing barrier that would support high margins.
What is the revenue exposure for manufacturers?
For a diversified dental-products company, the combination is unlikely to be material on a consolidated basis unless it is part of a broader local-anesthetic portfolio or has unusually strong regional distribution. Dental consumables companies often report revenue by segment rather than by individual anesthetic SKU.[4]
The more relevant financial metrics are:
- Dental consumables revenue
- Local-anesthetic unit volume
- Average selling price per cartridge
- Gross margin by product family
- Distributor concentration
- Manufacturing utilization
- Product complaints and recalls
- Geographic sales mix
A small product can still have strategic value if it anchors a distributor relationship or fills a complete dental-anesthetic portfolio.
What licensing deals involve epinephrine-prilocaine?
No major publicly disclosed licensing transaction appears to be tied specifically to the epinephrine bitartrate; prilocaine hydrochloride combination. Commercial rights for older dental anesthetics are more commonly transferred through product acquisitions, regional distribution agreements, contract manufacturing arrangements or portfolio transactions than through high-value molecule licenses.
Potential deal structures include:
- Regional commercialization rights.
- Private-label supply agreements.
- Acquisition of a dental-anesthetic portfolio.
- Contract manufacturing and cartridge filling.
- Distribution rights for specific concentrations or presentations.
Because the active ingredients are genericized, deal value would depend on regulatory approvals, supply continuity, manufacturing capability and distribution reach rather than patent life.
What patent litigation affects epinephrine-prilocaine?
No significant current patent litigation is apparent for the combination. The absence of litigation is consistent with the product’s age, expired active-ingredient rights and lack of a visible blocking Orange Book estate.
Litigation risk is more likely to involve:
- Manufacturing quality
- Product liability
- Adverse-event claims
- Labeling adequacy
- Supply agreements
- Regulatory compliance
- Trademark or trade-dress disputes
These risks can affect cost and availability without creating exclusivity for the product.
What generic launch risks exist?
A new generic entrant would face moderate technical and regulatory barriers but low patent barriers.
Regulatory and technical barriers
An applicant would need to demonstrate conformity with the reference product’s active ingredients, dosage form, strength, route of administration and quality attributes. Injectable dental products require controls for sterility, particulate matter, container closure, stability and dose uniformity.
Commercial barriers
The principal commercial risks are:
- Low selling prices
- Established distributor relationships
- Limited market size per SKU
- Need for reliable dental-cartridge manufacturing
- Switching costs at the purchasing, rather than clinical, level
- Competition from better-known articaine and lidocaine products
Launch scenarios
| Scenario |
Likely effect |
| New entrant with low price |
Accelerated price erosion |
| Entrant with reliable supply |
Share gain against intermittent suppliers |
| Private-label launch |
Lower brand visibility but stronger distributor penetration |
| Manufacturing disruption |
Temporary price and volume increase for available suppliers |
| Safety-driven substitution |
Long-term share loss to non-prilocaine products |
| Regional launch |
Limited national impact but meaningful local pressure |
How strong is the patent estate?
The patent estate is weak from a blocking perspective. The active ingredients are old, historical exclusivity has expired, and no meaningful current patent protection is apparent. The defensible assets are manufacturing capability, regulatory files, quality systems, customer relationships and distribution.
| Protection type |
Strength |
| Composition of matter |
Very weak |
| Fixed-dose formulation |
Weak |
| Method of use |
Weak |
| Orange Book exclusivity |
Weak or absent |
| Manufacturing know-how |
Moderate if specialized |
| Regulatory approvals |
Moderate operational value |
| Distribution network |
Potentially strong |
| Brand recognition |
Variable by market |
What is the geographic coverage?
The combination has the broadest commercial relevance in markets with established dental-care systems and routine use of injectable cartridge anesthetics. Geographic performance depends on local registration, pharmacy and dental procurement rules, reimbursement, import controls and the availability of competing articaine and lidocaine products.
The United States is a mature market with significant generic competition. European and other international markets may show different product shares because articaine use, dental cartridge standards and national procurement practices vary. A company with regional registrations and local supply may achieve better economics outside the United States than through a national U.S. branded launch.
Key Takeaways
- Epinephrine bitartrate; prilocaine hydrochloride is a mature dental local-anesthetic combination, commonly associated with Citanest Forte Dental.
- Prilocaine provides local anesthesia, while epinephrine extends local effect through vasoconstriction.
- The active ingredients and core product rights are long genericized.
- No meaningful current patent or regulatory exclusivity appears to support premium pricing.
- Paragraph IV litigation and biosimilar risk are not material commercial issues.
- Articaine with epinephrine and lidocaine with epinephrine are the principal competitive pressures.
- Product-level revenue is not publicly disclosed by major manufacturers.
- The financial outlook is stable to declining, with upside tied to supply reliability and distributor access.
- Manufacturing, sterilization, cartridge supply and regulatory compliance are more important barriers than patents.
- Prilocaine-associated methemoglobinemia risk can drive substitution toward other local anesthetics.
FAQs
Is prilocaine with epinephrine a generic drug?
Yes. Prilocaine hydrochloride and epinephrine are long-established small molecules, and the combination is commercially genericized.
Does epinephrine-prilocaine have biosimilars?
No. Biosimilars apply to biological products. This combination is a conventional small-molecule injectable.
Can a dentist substitute articaine for prilocaine?
A dentist may select another local anesthetic when clinically appropriate, but substitution depends on the procedure, patient characteristics, formulation, concentration and applicable prescribing rules.
Is Citanest Forte Dental still a growth product?
No. It is a mature dental consumable. Growth is more likely to come from procedure volumes, geographic expansion or supply disruption affecting competitors than from therapeutic innovation.
What is the main investment risk for an epinephrine-prilocaine supplier?
The main risks are price erosion, weak product differentiation, manufacturing interruption, distributor concentration and substitution by articaine or lidocaine products.
References
-
U.S. Food and Drug Administration. (n.d.). Citanest Forte Dental: Prilocaine hydrochloride and epinephrine bitartrate injection prescribing information. FDA/DailyMed labeling.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Citanest Forte Dental, NDA 017455. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
Dentsply Sirona Inc. (2024). Annual report on Form 10-K. U.S. Securities and Exchange Commission. https://www.sec.gov/edgar/browse/?CIK=818479
